---
document_datetime: 2025-12-02 05:38:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sycrest.html
document_name: sycrest.html
version: success
processing_time: 0.1063821
conversion_datetime: 2025-12-28 02:11:09.866395
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sycrest

[RSS](/en/individual-human-medicine.xml/66118)

##### Authorised

This medicine is authorised for use in the European Union

asenapine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Sycrest](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Sycrest. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sycrest.

Expand section

Collapse section

## What is Sycrest?

Sycrest is a medicine that contains the active substance asenapine. It is available as sublingual tablets (5 and 10 mg). Sublingual tablets are tablets that are placed under the tongue, where they dissolve.

## What is Sycrest used for?

Sycrest is used to treat moderate to severe manic episodes (extremely high mood) in adults (aged 18 years or over) with bipolar disorder, a mental illness in which patients have periods of abnormally high mood alternating with periods of normal or depressed mood.

The medicine can only be obtained with a prescription.

## How is Sycrest used?

The recommended starting dose of Sycrest is 5 mg twice a day, one dose in the morning and one in the evening. This dose can be increased to 10 mg twice a day depending on how the patient responds.

Sycrest tablets should not be chewed or swallowed. When taken in combination with other medicines, Sycrest should be taken last. The patient should avoid eating or drinking for 10 minutes after taking the medicine.

## How does Sycrest work?

The active substance in Sycrest, asenapine, is an antipsychotic medicine. It is known as an 'atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by 'neurotransmitters', chemicals that allow nerve cells to communicate with each other. It is thought that Sycrest works by blocking receptors for the neurotransmitters 5?hydroxytrypamine (also called serotonin) and dopamine. Since these neurotransmitters are involved in bipolar disorder, Sycrest helps to normalise the activity of the brain, reducing the symptoms of the disease.

## How has Sycrest been studied?

Four main studies looked at the use of Sycrest for manic episodes in bipolar disorder. In two of these studies, a total of 977 adult patients were given Sycrest, olanzapine (another antipsychotic medicine) or placebo (a dummy treatment) over three weeks. The other two studies lasted longer: one compared Sycrest with olanzapine over nine weeks in patients who had come from the short-term studies; and the other was a 12-week 'add on' study, in which 326 patients who were already being treated with another medicine (lithium or valproic acid) were also given either Sycrest or placebo. The main measure of effectiveness was the change in the patients' 'Young mania rating scale' (Y-MRS) score. The Y-MRS rates the severity of symptoms of manic episodes on a scale from 0 to 60.

Sycrest was also studied in patients with schizophrenia. The studies included short- and long-term studies in patients receiving Sycrest, other medicines for schizophrenia (olanzapine, risperidone or haloperidol) or placebo.

## What benefit has Sycrest shown during the studies?

Sycrest was effective at treating manic episodes in patients with bipolar disorder. In the first short-term study, the reductions in Y-MRS score after three weeks were 11.5 and 14.6 points for Sycrest and olanzapine, respectively, compared with 7.8 points for placebo. The reductions for the second short-term study were 10.8 and 12.6 points for Sycrest and olanzapine, respectively, and 5.5 for placebo.

In the first long-term study, a reduction in Y-MRS score of 12.9 was seen in patients taking Sycrest compared with 16.2 in patients taking olanzapine. In the second long-term study, the reductions in Y?MRS score were 10.3 and 7.9 for Sycrest and placebo, respectively, after three weeks and 12.7 and 9.3 after 12 weeks.

The studies on schizophrenia were not considered to have shown sufficient evidence of the effectiveness in treating this disease.

## What is the risk associated with Sycrest?

The most common side effects with Sycrest (seen in more than 1 patient in 10) are anxiety and somnolence (sleepiness). For the full list of side effects and restrictions, see the package leaflet.

## Why has Sycrest been approved?

The CHMP decided that Sycrest's benefits are greater than its risks and recommended that it be given marketing authorisation for the treatment of moderate to severe manic episodes in patients with bipolar disorder.

The CHMP, however, did not recommend that the medicine be authorised to treat schizophrenia because of the lack of effectiveness shown in this illness.

## What measures are being taken to ensure the safe and effective use of Sycrest?

A risk management plan has been developed to ensure that Sycrest is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Sycrest, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Sycrest

The European Commission granted a marketing authorisation valid throughout the European Union for Sycrest on 1 September 2010.

For more information about treatment with Sycrest, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Sycrest : EPAR - Summary for the public

Reference Number: EMA/431731/2010

English (EN) (83.12 KB - PDF)

**First published:** 22/09/2010

**Last updated:** 26/01/2016

[View](/en/documents/overview/sycrest-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-750)

български (BG) (112.73 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/bg/documents/overview/sycrest-epar-summary-public_bg.pdf)

español (ES) (83.71 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/es/documents/overview/sycrest-epar-summary-public_es.pdf)

čeština (CS) (110.16 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/cs/documents/overview/sycrest-epar-summary-public_cs.pdf)

dansk (DA) (83.25 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/da/documents/overview/sycrest-epar-summary-public_da.pdf)

Deutsch (DE) (84.15 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/de/documents/overview/sycrest-epar-summary-public_de.pdf)

eesti keel (ET) (82.52 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/et/documents/overview/sycrest-epar-summary-public_et.pdf)

ελληνικά (EL) (114.89 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/el/documents/overview/sycrest-epar-summary-public_el.pdf)

français (FR) (83.61 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/fr/documents/overview/sycrest-epar-summary-public_fr.pdf)

hrvatski (HR) (105.97 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/hr/documents/overview/sycrest-epar-summary-public_hr.pdf)

italiano (IT) (83.01 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/it/documents/overview/sycrest-epar-summary-public_it.pdf)

latviešu valoda (LV) (107.11 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/lv/documents/overview/sycrest-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (108.1 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/lt/documents/overview/sycrest-epar-summary-public_lt.pdf)

magyar (HU) (104.84 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/hu/documents/overview/sycrest-epar-summary-public_hu.pdf)

Malti (MT) (111.34 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/mt/documents/overview/sycrest-epar-summary-public_mt.pdf)

Nederlands (NL) (82.88 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/nl/documents/overview/sycrest-epar-summary-public_nl.pdf)

polski (PL) (111.17 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/pl/documents/overview/sycrest-epar-summary-public_pl.pdf)

português (PT) (83.95 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/pt/documents/overview/sycrest-epar-summary-public_pt.pdf)

română (RO) (106.56 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/ro/documents/overview/sycrest-epar-summary-public_ro.pdf)

slovenčina (SK) (108.72 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/sk/documents/overview/sycrest-epar-summary-public_sk.pdf)

slovenščina (SL) (103.86 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/sl/documents/overview/sycrest-epar-summary-public_sl.pdf)

Suomi (FI) (82.14 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/fi/documents/overview/sycrest-epar-summary-public_fi.pdf)

svenska (SV) (83.03 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

26/01/2016

[View](/sv/documents/overview/sycrest-epar-summary-public_sv.pdf)

## Product information

Sycrest : EPAR - Product information

English (EN) (358.72 KB - PDF)

**First published:** 22/09/2010

**Last updated:** 07/12/2022

[View](/en/documents/product-information/sycrest-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-960)

български (BG) (479.42 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/bg/documents/product-information/sycrest-epar-product-information_bg.pdf)

español (ES) (362.38 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/es/documents/product-information/sycrest-epar-product-information_es.pdf)

čeština (CS) (449.53 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/cs/documents/product-information/sycrest-epar-product-information_cs.pdf)

dansk (DA) (402.57 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/da/documents/product-information/sycrest-epar-product-information_da.pdf)

Deutsch (DE) (437.87 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/de/documents/product-information/sycrest-epar-product-information_de.pdf)

eesti keel (ET) (434.2 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/et/documents/product-information/sycrest-epar-product-information_et.pdf)

ελληνικά (EL) (663.77 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/el/documents/product-information/sycrest-epar-product-information_el.pdf)

français (FR) (432.96 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/fr/documents/product-information/sycrest-epar-product-information_fr.pdf)

hrvatski (HR) (443.33 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/hr/documents/product-information/sycrest-epar-product-information_hr.pdf)

íslenska (IS) (380.83 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/is/documents/product-information/sycrest-epar-product-information_is.pdf)

italiano (IT) (683.34 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/it/documents/product-information/sycrest-epar-product-information_it.pdf)

latviešu valoda (LV) (473.44 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/lv/documents/product-information/sycrest-epar-product-information_lv.pdf)

lietuvių kalba (LT) (456.09 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/lt/documents/product-information/sycrest-epar-product-information_lt.pdf)

magyar (HU) (640.03 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/hu/documents/product-information/sycrest-epar-product-information_hu.pdf)

Malti (MT) (509 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/mt/documents/product-information/sycrest-epar-product-information_mt.pdf)

Nederlands (NL) (463.99 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/nl/documents/product-information/sycrest-epar-product-information_nl.pdf)

norsk (NO) (590.03 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/no/documents/product-information/sycrest-epar-product-information_no.pdf)

polski (PL) (510.2 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/pl/documents/product-information/sycrest-epar-product-information_pl.pdf)

português (PT) (459.58 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/pt/documents/product-information/sycrest-epar-product-information_pt.pdf)

română (RO) (677.31 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/ro/documents/product-information/sycrest-epar-product-information_ro.pdf)

slovenčina (SK) (489.31 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/sk/documents/product-information/sycrest-epar-product-information_sk.pdf)

slovenščina (SL) (622.75 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/sl/documents/product-information/sycrest-epar-product-information_sl.pdf)

Suomi (FI) (446.37 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/fi/documents/product-information/sycrest-epar-product-information_fi.pdf)

svenska (SV) (387.73 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

07/12/2022

[View](/sv/documents/product-information/sycrest-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0046 07/12/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sycrest : EPAR - All Authorised presentations

English (EN) (50.04 KB - PDF)

**First published:** 22/09/2010

**Last updated:** 20/01/2015

[View](/en/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-806)

български (BG) (58.94 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/bg/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_bg.pdf)

español (ES) (56.21 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/es/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.95 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/cs/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (56.53 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/da/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (57 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/de/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (50.33 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/et/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (58.98 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/el/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_el.pdf)

français (FR) (56.9 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/fr/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (55.91 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/hr/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (62.84 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/is/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_is.pdf)

italiano (IT) (61.92 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/it/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (58.09 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/lv/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (57.37 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/lt/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (56.67 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/hu/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (52.27 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/mt/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.66 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/nl/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (79.64 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/no/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.08 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/pl/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_pl.pdf)

português (PT) (56.45 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/pt/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_pt.pdf)

română (RO) (74.48 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/ro/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.91 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/sk/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (68.18 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/sl/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (61.97 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/fi/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (56.19 KB - PDF)

**First published:**

22/09/2010

**Last updated:**

20/01/2015

[View](/sv/documents/all-authorised-presentations/sycrest-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sycrest Active substance asenapine maleate International non-proprietary name (INN) or common name asenapine Therapeutic area (MeSH) Bipolar Disorder Anatomical therapeutic chemical (ATC) code N05AH05

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.

## Authorisation details

EMA product number EMEA/H/C/001177 Marketing authorisation holder

N.V. Organon

Kloosterstraat 6

Opinion adopted 24/06/2010 Marketing authorisation issued 01/09/2010 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sycrest : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (183.32 KB - PDF)

**First published:** 14/03/2011

**Last updated:** 07/12/2022

[View](/en/documents/procedural-steps-after/sycrest-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Sycrest : EPAR - Public assessment report

Reference Number: EMA/CHMP/583011/2010

English (EN) (1.17 MB - PDF)

**First published:** 22/09/2010

**Last updated:** 22/09/2010

[View](/en/documents/assessment-report/sycrest-epar-public-assessment-report_en.pdf)

CHMP positive summary of opinion for Sycrest

Adopted

Reference Number: EMA/CHMP/397789/2010

English (EN) (70.8 KB - PDF)

**First published:** 25/06/2010

**Last updated:** 25/06/2010

[View](/en/documents/smop-initial/chmp-positive-summary-opinion-sycrest_en.pdf)

#### More information on Sycrest

- [EMEA-000228-PIP01-08-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000228-pip01-08-m04)
- [An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England (OBSERVA) - post-authorisation study](https://catalogues.ema.europa.eu/study/28401)
- [An Observational Drug Utilization Study of SYCREST® (asenapine) in the United Kingdom (P08308) - post-authorisation study](https://catalogues.ema.europa.eu/study/24560)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 07/12/2022

## Share this page

[Back to top](#main-content)